LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Lista de Ações・Denali Therapeutics Inc

Denali Therapeutics Inc

Fechado

SetorSaúde

20.43 12.44

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

18.17

Máximo

20.46

Indicadores-chave
By Trading Economics
Rendimento	-1.6M -129M
Funcionários	503
EBITDA	8.9M -125M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+94.27% upside

Dividendos
By Dow Jones
Próximos Ganhos	11 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-93M 3.2B
Abertura anterior	7.99
Fecho anterior	20.43

Sentimento de Notícias

By Acuity

10%

90%

7 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

13.355 / 16.44 Suporte e Resistência

Denali Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de mai. de 2026, 23:43 UTC

Notícias Principais

New Zealand's Unemployment Rate Falls in 1Q

5 de mai. de 2026, 23:20 UTC

Ações em Alta

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 de mai. de 2026, 21:48 UTC

Ganhos

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 de mai. de 2026, 21:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 de mai. de 2026, 00:00 UTC

Conversa de Mercado

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 de mai. de 2026, 22:26 UTC

Conversa de Mercado

AMD Data-Center Business Continues to Surge -- Market Talk

5 de mai. de 2026, 22:20 UTC

Conversa de Mercado

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 de mai. de 2026, 22:08 UTC

Ganhos

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 de mai. de 2026, 22:07 UTC

Ganhos

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:48 UTC

Ganhos

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 de mai. de 2026, 21:48 UTC

Ganhos

Pan American Silver 1Q Rev $1.2B >PAAS

5 de mai. de 2026, 21:42 UTC

Ganhos

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 de mai. de 2026, 21:38 UTC

Ganhos

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:30 UTC

Ganhos

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 de mai. de 2026, 21:29 UTC

Ganhos

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:26 UTC

Ganhos

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 de mai. de 2026, 21:25 UTC

Ganhos

Alcon Inc. 1Q EPS 39c >ALC.EB

5 de mai. de 2026, 21:25 UTC

Ganhos

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 de mai. de 2026, 21:24 UTC

Ganhos

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 de mai. de 2026, 21:18 UTC

Ganhos

Mistras Backs 2026 Rev $730M-$750M >MG

5 de mai. de 2026, 21:17 UTC

Ganhos

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 de mai. de 2026, 21:15 UTC

Ganhos

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 de mai. de 2026, 21:12 UTC

Ganhos

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 de mai. de 2026, 21:11 UTC

Ganhos

SSR Mining 1Q Rev $581.8M >SSRM

5 de mai. de 2026, 21:10 UTC

Ganhos

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 de mai. de 2026, 21:10 UTC

Ganhos

SSR Mining 1Q EPS $1.16 >SSRM

5 de mai. de 2026, 21:08 UTC

Ganhos

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 de mai. de 2026, 21:01 UTC

Ganhos

Intact Financial 1Q EPS C$4.12 >IFC.T

5 de mai. de 2026, 21:01 UTC

Ações em Alta

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Comparação entre Pares

Variação de preço

Denali Therapeutics Inc Previsão

Preço-alvo

By TipRanks

94.27% parte superior

Previsão para 12 meses

Média 36.27 USD 94.27%

Máximo 42 USD

Mínimo 30 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

Comprar

Manter

Vender

Com base em 14 analistas que deram avaliações de ações para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

13.355 / 16.44Suporte e Resistência

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentimento

By Acuity

7 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.